Keyphrases
Epithelial Ovarian Cancer
53%
Ovarian Cancer
50%
Platinum Sensitivity
47%
BRCA mutation
47%
Pegylated Liposomal Doxorubicin
36%
Chemotherapy
33%
Overall Survival
33%
Olaparib
29%
Rucaparib
29%
Progression-free Survival
26%
Phase II Study
25%
Carboplatin
25%
Placebo
23%
Ovarian Cancer Patients
23%
Phase II Trial
23%
Confidence Interval
22%
Endometrial Cancer
20%
Monotherapy
19%
Retrospective Analysis
19%
PARP Inhibitor (PARPi)
18%
Maintenance Therapy
18%
Paclitaxel
17%
Recurrent Ovarian Cancer
17%
Median Progression-free Survival
17%
Primary Peritoneal Cancer
16%
Advanced Ovarian Cancer
16%
Serous Ovarian Cancer
16%
Randomized Phase III Trial
16%
BRCA mutation Carriers
16%
Median Overall Survival
16%
Maintenance Treatment
15%
Platinum Resistance
15%
Doxorubicin
14%
BRCA2 mutation
14%
BRCA1, BRCA2
14%
Health-related Quality of Life
14%
Platinum-based Chemotherapy
14%
Partial Response
13%
Cisplatin
12%
Complete Response
12%
Disease Progression
12%
Response to Chemotherapy
12%
Weekly Topotecan
12%
Metastatic Breast Cancer
12%
Microsatellite Instability-high (MSI-H)
12%
Pembrolizumab
12%
Relapsed Ovarian Cancer
12%
Recurrent Endometrial Cancer
12%
ENGOT
12%
Israeli
12%
Medicine and Dentistry
Ovarian Cancer
100%
Krukenberg Tumor
64%
Overall Survival
44%
BRCA Mutation
37%
Progression Free Survival
36%
Diseases
35%
Maintenance Therapy
30%
Breast Cancer
29%
Malignant Neoplasm
26%
BRCA1
26%
Placebo
25%
Olaparib
24%
Rucaparib
24%
Uterine Cancer
24%
Doxorubicin
24%
Quality of Life
20%
Monotherapy
19%
Carboplatin
17%
BRCA2
14%
Gemcitabine
14%
Recurrent Ovarian Cancer
13%
Topotecan
13%
Adverse Event
13%
Cervical Cancer
12%
BRCA Gene
12%
Female Genital Tract Cancer
12%
Pembrolizumab
12%
Health Care Cost
11%
Disease Exacerbation
11%
Recurrent Disease
11%
Paclitaxel
10%
Cost-Effectiveness Analysis
10%
Phase II Trials
9%
Gamma Urogastrone
9%
Phase III Trials
8%
Primary Peritoneal Carcinoma
8%
Genetic Screening
8%
Cardiotoxicity
8%
Metastatic Breast Cancer
8%
Positron Emission Tomography-Computed Tomography
8%
Letrozole
8%
Epidermal Growth Factor Receptor 2
8%
Microsatellite Instability
8%
DNA Mismatch Repair
8%
PARP Inhibitor
8%
Hazard Ratio
6%
Gene Mutation
6%
Neoplasm
6%
Anemia
6%
Germ Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Carcinoma
57%
Ovary Cancer
50%
Doxorubicin
39%
Chemotherapy
32%
Overall Survival
30%
Progression Free Survival
24%
Paclitaxel
23%
Carboplatin
22%
Breast Cancer
22%
Diseases
17%
Endometrium Cancer
16%
Malignant Neoplasm
16%
Placebo
14%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
13%
Cisplatin
13%
Gamma Urogastrone
13%
Topotecan
12%
Olaparib
12%
Cardiotoxicity
12%
Metastatic Breast Cancer
12%
Epidermal Growth Factor Receptor 2
12%
Pembrolizumab
12%
Phase II Trials
12%
Adverse Event
11%
Disease Exacerbation
10%
Peritoneum Cancer
10%
Tolerability
10%
Solid Malignant Neoplasm
10%
Hormone Receptor
10%
Carcinoma
9%
Monotherapy
9%
Anthracycline
9%
Recurrent Disease
8%
Rucaparib
8%
Liposome
8%
Letrozole
8%
Antitumor Activity
7%
Trastuzumab
6%
Docetaxel
6%
Neutropenia
5%
Neoplasm
5%
Phase III Trials
5%
Fulvestrant
5%
Neuropathy
5%
Endocrine Therapy
5%